EUCTR2007-002667-28-ES进行中（未招募）1 期
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, en pacientes con varias crisis para comparar la eficacia y la seguridad de MK-0974 oral y placebo en el tratamiento agudo de la migraña con o sin aura. - Acute Treatment of Multiple Migraines With or Without Aura in Adults
Merck Sharp & Dohme de España, S.A.0 个研究点目标入组 1,834 人开始时间: 2008年5月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,834
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a.Patient has had a history of migraine with or without aura > 1 year with = 1 and = 8 moderate or severe migraine attacks per month in the 2 months prior to screening that typically last between 4 to 72 hours untreated (see Appendix 6.1 and ICHD II Attachment for IHS migraine definitions).
- •b.Women and men of childbearing potential must use acceptable contraception throughout the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a.Patient has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours.
- •b.Patient has basilar or hemiplegic migraine headache.
- •c.Patient has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the 3 months prior to screening.
- •d.Patient is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening.
- •e.Patient was > 50 years old at age of migraine onset.
- •f.Patient has clinical, laboratory, or ECG evidence of uncontrolled hypertension (defined as SBP of =150 mm Hg and/or DBP of =95 mm Hg), uncontrolled diabetes, HIV disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the investigator.
- •g.Patient has myocardial infarction, unstable angina, coronary artery bypass surgery, or other revascularization procedure, stroke, or transient ischemic attack within 3 months of screening.
- •h.Patient has taken any of the following medications in 1 mo. prior to screening and throughout the study period:
- •-Potent CYP3A4 inhibitors, including but not limited to: (e.g. cyclosporine, systemic (oral/IV) itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, nefazodone, HIV protease inhibitors)
- •-Potent CYP3A4 inducers, including but not limited to: rifampicin, rifabutin, carbamazepine, phenytoin, barbiturates, systemic glucocorticoids (replacements and inhaled are permitted), nevirapine, efavirenz, pioglitazone, primidone, St. Johns wort
- •-Specific CYP3A4 substrates: cisapride, pimozide, astemizole, terfenadine. Concomitant use of other CYP3A4 substrates is permitted, however, these medications should be administered with appropriate caution due to the potential for drug-drug interaction (e.g., theophylline, ergot derivatives)
- •i.Patient has previously treated with study medication in a MK-0974 study.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMigraineMedDRA version: 9.1Level: LLTClassification code 10027599Term: MigraineEUCTR2007-002667-28-ATMerck Sharp & Dohme GmbH1,834
进行中（未招募）
1 期
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) who have Inadequate Glycemic ControlEUCTR2015-000804-24-ITAstraZeneca AB321
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMedDRA version: 9.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2007-002667-28-DKMerck & Co. Inc.1,834
进行中（未招募）
1 期
A study to evaluate the effect of dapagliflozin on blood glucose level and renal safety in patients with Type 2 DiabetesType 2 Diabetes Mellitus with Moderate Renal Impairment (CKD 3A)EUCTR2015-000804-24-PLAstraZeneca AB302
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMigraineEUCTR2007-002667-28-SEMerck Sharp & Dohme (Sweden) AB1,834